Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer

OBJECTIVE: To investigate the relationship between BRCA mutation status and response to taxane-based chemotherapy, since BRCA mutation carriers with prostate cancer appear to have worse survival than non-carriers and docetaxel improves survival in patients with castration-resistant prostate cancer....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Gallagher, David J., Cronin, Angel M., Milowsky, Matthew I., Morris, Michael J., Bhatia, Jasmine, Scardino, Peter T., Eastham, James A., Offit, Kenneth, Robson, Mark E.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3971723/
https://ncbi.nlm.nih.gov/pubmed/21756279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2011.10292.x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items